Physician profile
Nour Hamade
NPI 1275985632
$5,134.79
in general payments reported to CMS, 2019-2025
19 companies · $1,680 in 2025
The $1,680 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.59 · 2021: $17.48 · 2022: $375 · 2023: $1,200 · 2024: $1,826 · 2025: $1,680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,620 · Education: $85.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,620.05 |
| Education | $85.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,913.85 | 2022-2025 | |
| Genzyme Corporation | $552.27 | 2022-2025 | |
| Janssen Biotech, INC. | $519.94 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $333.06 | 2023-2025 | Entyvio, Gattex |
| Intercept Pharmaceuticals, INC. | $270.51 | 2023-2024 | Ocaliva |
| Pfizer INC. | $239.69 | 2024-2025 | |
| Celgene Corporation | $239.52 | 2023-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $214.31 | 2022-2023 | Zeposia |
| Boston Scientific Corporation | $136.24 | 2021-2024 | |
| Regeneron Pharmaceuticals, INC. | $128.70 | 2023 | Dupixent |
| Regeneron Healthcare Solutions, INC. | $127.75 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $93.58 | 2024-2025 | Ibsrela |
| Medtronic, INC. | $91.53 | 2025 | Manoscan |
| Celltrion USA INC. | $72.46 | 2025 | Vegzelma |
| Madrigal Pharmaceuticals | $59.55 | 2025 | Rezdiffra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $40.66 | 2023-2024 | Visiglide, Disposable Biopsy Forceps |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.59 | 2019 | |
| Lilly USA, LLC | $33.76 | 2024 | Omvoh |
| Cook Medical LLC | $30.82 | 2023 | Fusion |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nour Hamade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.